Processa Pharmaceuticals, Inc. Purchase Obligation
Processa Pharmaceuticals, Inc. (PCSA) had Purchase Obligation of $1.00 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:PurchaseObligation · last filed 2026-08-14
- 2026-06-30: Purchase Obligation $1.00M.
- 2020-12-31: Purchase Obligation $6.10M.
- 2019-12-31: Purchase Obligation $0.00.
- 2019-09-30: Purchase Obligation $16.00K.
| Period end | Purchase Obligation | Purchase Obligation as first filed |
|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-14 | |
| 2020-12-31 | $6.10M 10-K · filed 2021-03-25 | |
| 2019-12-31 | $0.00 10-K · filed 2020-03-06 | |
| 2019-09-30 | $16.00K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $16.00K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $23.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $35.00K 10-K · filed 2020-03-06 | |
| 2018-09-30 | $41.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $110.00K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $1.01M 10-Q · filed 2018-05-21 | |
| 2017-12-31 | $896.00K 10-K/A · filed 2019-04-08 | $895.74K 10-K · filed 2018-04-16 |
| 2016-12-31 | $0.00 10-K · filed 2018-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |